Literature DB >> 1565844

The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75).

C Scheibenbogen1, U Keilholz, M Richter, R Andreesen, W Hunstein.   

Abstract

Human monocytes constitutively express the intermediate-affinity interleukin-2 receptor (IL2R) p75, while freshly isolated monocytes lack the low-affinity IL2R p55 (Tac antigen, CD25). Lipopolysaccharide (LPS) upregulates expression of p75 and effectively induces surface expression of CD25 on human monocytes within 18 h, as detected by two-colour FACS analysis on 59.5 +/- 7.6% of cells. IL2-binding studies using biotinylated IL2 reveal the presence of a functional high-affinity receptor on LPS-activated monocytes. Soluble CD25 (sCD25) is not released into supernatants of elutriation-purified monocytes cultured for 24 h with 100 ng/ml LPS. When these monocytes are cultured for up to 7 days in the presence of serum to induce differentiation into macrophages, increasing amounts of sCD25 can be measured in the 24-h supernatants induced with LPS (173 +/- 86 U/ml at day 7), whereas the percentage of CD25+ cells (14.8 +/- 14.1% at day 7) is significantly lower than in monocytes. Thus, the cell surface expression and release of CD25 is differentially regulated in activated monocytes and macrophages.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1565844     DOI: 10.1016/0923-2494(92)80077-x

Source DB:  PubMed          Journal:  Res Immunol        ISSN: 0923-2494


  10 in total

1.  Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection.

Authors:  S D Lawn; B D Roberts; G E Griffin; T M Folks; S T Butera
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Authors:  Remi M M Vanmaris; Ger T Rijkers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 3.  Daclizumab therapy for multiple sclerosis.

Authors:  Bibiana Bielekova
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

4.  EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.

Authors:  Janine Schmidt; Irina Bonzheim; Julia Steinhilber; Ivonne A Montes-Mojarro; Carlos Ortiz-Hidalgo; Wolfram Klapper; Falko Fend; Leticia Quintanilla-Martínez
Journal:  Lab Invest       Date:  2017-06-05       Impact factor: 5.662

5.  IFNs Drive Development of Novel IL-15-Responsive Macrophages.

Authors:  Scott M Gordon; Mailyn A Nishiguchi; Julie M Chase; Sneha Mani; Monica A Mainigi; Edward M Behrens
Journal:  J Immunol       Date:  2020-07-20       Impact factor: 5.422

6.  LPS-induced systemic inflammation is more severe in P2Y12 null mice.

Authors:  Elisabetta Liverani; Mario C Rico; Laxmikausthubha Yaratha; Alexander Y Tsygankov; Laurie E Kilpatrick; Satya P Kunapuli
Journal:  J Leukoc Biol       Date:  2013-10-18       Impact factor: 4.962

7.  Development and validation of a bovine macrophage specific cDNA microarray.

Authors:  Kirsty Jensen; Richard Talbot; Edith Paxton; David Waddington; Elizabeth J Glass
Journal:  BMC Genomics       Date:  2006-09-01       Impact factor: 3.969

Review 8.  The cytokine response to physical activity and training.

Authors:  A I Moldoveanu; R J Shephard; P N Shek
Journal:  Sports Med       Date:  2001-02       Impact factor: 11.136

Review 9.  Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action.

Authors:  V Sánchez-Margalet; C Martín-Romero; J Santos-Alvarez; R Goberna; S Najib; C Gonzalez-Yanes
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

10.  Establishing Porcine Monocyte-Derived Macrophage and Dendritic Cell Systems for Studying the Interaction with PRRSV-1.

Authors:  Helen Singleton; Simon P Graham; Katherine B Bodman-Smith; Jean-Pierre Frossard; Falko Steinbach
Journal:  Front Microbiol       Date:  2016-06-02       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.